Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
386.20
+16.40 (4.43%)
At close: Mar 6, 2026
59.06%
Market Cap 86.23B
Revenue (ttm) 1.64B
Net Income (ttm) -791.34M
Shares Out 233.19M
EPS (ttm) -3.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 581,902
Average Volume 454,653
Open 360.00
Previous Close 369.80
Day's Range 360.00 - 390.40
52-Week Range 225.20 - 581.00
Beta 0.45
RSI 44.65
Earnings Date Mar 24, 2026

About HKG:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally. Its product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC ta... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 1,870
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6990
Full Company Profile

Financial Performance

In 2024, HKG:6990's revenue was 1.93 billion, an increase of 25.48% compared to the previous year's 1.54 billion. Losses were -266.77 million, -48.92% less than in 2023.

Financial numbers in CNY Financial Statements

News

Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up

(RTTNews) - Crescent Biopharma, Inc. (CBIO), on Thursday announced an exclusive partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology therapeutics, i...

3 months ago - Nasdaq